• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New CDISC Standards Make Sites’ AE Reporting Easier

New CDISC Standards Make Sites’ AE Reporting Easier

Standards-360x240.png
April 26, 2021
Charlie Passut

After a two-year collaboration, two industry nonprofits have unveiled an approach for safety reporting that will help sites reduce the amount of duplicate adverse event (AE) data entry they currently do to meet sponsor and regulatory requirements.

With the help of industry consortium TransCelerate, the Clinical Data Interchange Standards Consortium (CDISC) has identified 156 key factors that should be included in AE safety reports and mapped out how data fields could be added to electronic case report forms (eCRF) to capture all necessary information once and automatically produce standardized reports.

The standards CDISC released last week in a 50-page report follow the principles detailed in the International Council on Harmonization’s (ICH) E2B guideline on clinical safety data management and individual case safety reports (ICSR).

“The aim of this is to make the process of submitting ICSRs to regulators easier because there’s a structure now,” CDISC Project Manager John Owen told CenterWatch Weekly.

The new standards are an update to CDISC’s existing standards, first released in 2013, and for the first time include a format for reporting specifically on serious adverse events (SAE).

“Now this additional data can be entered once and transferred to a sponsor organization’s safety database so they have the information they need,” Owen said. “It’s really expanding the ability to reduce duplicate data entry.”

CDISC said that it highly recommends sites record only one diagnosis, sign or symptom per line of the eCRF, indicate whether the cause of an AE is related to the study treatment and cannot be reasonably explained by other factors, and record changes made to the study treatment in response to an AE. CDISC also strongly recommended that after sponsors receive the data from sites, they conduct a causality assessment and try to figure out whether the AE or SAE could have been related to their product, treatment or intervention.

Most of the SAE standards, 71 in total, address the characteristics of trial participants and cover a variety of topics, including demographics, medical history, relevant procedures, vital signs, past drug history and death details. CDISC recommended that a site’s clinical investigator assign a unique identifier to each trial participant and provide such information as relevant medical conditions or events as defined in the protocol, names of any relevant medical procedures, concomitant medications and current conditions, the reported primary cause of a participant’s death, if necessary, and whether an autopsy was performed.

Data from laboratory tests and procedures performed to diagnose or confirm an AE or SAE event should be included in an eCRF, CDISC said, with both positive and negative results reported.

The narrative portion of an SAE report — where all relevant clinical and related information is summarized into a comprehensive, standalone “medical story” to either support or disprove a diagnosis for an adverse drug reaction — should include patient characteristics, therapy details, prior medical history, the patient’s clinical course of events and any laboratory evidence. The information should be presented in a logical time sequence, ideally in chronological order of the patient’s experience, rather than in chronological order of when the information was received, according to CDISC.

CDISC based its recommended narrative structure on ICH E3 — Structure and Content of Clinical Study Reports guideline — and said the narrative should be able to answer four key questions:

  • Is a diagnosis possible?
  • Have the relevant diagnostic procedures been performed?
  • Were alternative causes of the event/reaction(s) considered?
  • What additional information may be needed to allow for the final conclusion regarding whether the SAE was caused by the product?

To request a copy of CDISC’s report, click here: https://bit.ly/2QTcLAs.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing